Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3187-3194

  Reigadas, S ^a,b   Masquelier, B ^a,b   Calmels, C ^a   Laguerre, M ^c   Lazaro, E ^d   Vandenhende, M ^e   Neau, D ^a,b   Fleury, H ^a,b   Andreola M L ^a  

^a University Victor Segalen   (France)

^b HÔPITAL PELLEGRIN   (France)

^c INSTITUT EUROPÉEN DE CHIMIE ET BIOLOGIE   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e HÔPITAL SAINT ANDRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; RALTEGRAVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CATALYSIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; EXPRESSION VECTOR; GENE MUTATION; GENETIC ASSOCIATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; MOLECULAR MODEL; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RNA PROCESSING; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; WILD TYPE;

DRUG RESISTANCE, VIRAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MUTATION; PYRROLIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79959214013     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00071-11     Document Type: Article

References (39)

1. Armenia, D., et al. 2010. Impact of baseline HIV-1 integrase mutations with virological outcome in patients starting a raltegravir-containing regimen, abstr. 28, p. 27-28. Eighth Eur. Drug Resist. Workshop, Sorrento, Italy, 17 to 19 March 2010.
2. Asante-Appiah, E., and A. M. Skalka. 1997. Molecular mechanisms in retrovirus DNA integration. Antiviral Res. 36:139-156.
3. Barreca, M. L., N. Iraci, L. De Luca, and A. Chimirri. 2009. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem 4:1446-1456.
4. Bonnenfant, S., et al. 2004. Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J. Virol. 78:5728-5736. (Pubitemid 38661660)
5. Canducci, F., et al. 2010. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J. Antimicrob. Chemother. 65:425-433.
6. Canducci, F., et al. 2009. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 23:455-460.
7. Caumont, A. B., et al. 1996. Expression of functional HIV-1 integrase in the yeast Saccharomyces cerevisiae leads to the emergence of a lethal phenotype: potential use for inhibitor screening. Curr. Genet. 29:503-510.
8. Ceccherini-Silberstein, F., et al. 2010. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob. Agents Chemother. 54:3938-3948.
9. Cooper, D. A., et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
10. Delelis, O., et al. 2009. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 37:1193-1201.
11. de Soultrait, V. R., et al. 2002. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J. Mol. Biol. 324:195-203.
12. Engelman, A., K. Mizuuchi, and R. Craigie. 1991. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 67:1211-1221. (Pubitemid 121001533)
13. Fransen, S., et al. 2009. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 83:11440-11446.
14. Grinsztejn, B., et al. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269. (Pubitemid 46553846)
15. Hare, S., S. S. Gupta, E. Valkov, A. Engelman, and P. Cherepanov. 2010. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464:232-236.
16. Hare, S., et al. 2010. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl. Acad. Sci. U. S. A. 107: 20057-20062.
17. Hazuda, D. J., et al. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650. (Pubitemid 30070911)
18. Krishnan, L., et al. 2010. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc. Natl. Acad. Sci. U. S. A. 107:15910-15915.
19. Lesbats, P., et al. 2008. In vitro initial attachment of HIV-1 integrase to viral ends: control of the DNA specific interaction by the oligomerization state. Nucleic Acids Res. 36:7043-7058.
20. Maertens, G. N., S. Hare, and P. Cherepanov. 2010. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 468:326-329.
21. Marchand, C., K. Maddali, M. Metifiot, and Y. Pommier. 2009. HIV-1 IN inhibitors: 2010 update and perspectives. Curr. Top. Med. Chem. 9:1016-1037.
22. Markowitz, M., et al. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515.
23. Metifiot, M., et al. 2010. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. Biochemistry 49:3715-3722.
24. Metifiot, M., C. Marchand, K. Maddali, and Y. Pommier. 2010. Resistance to integrase inhibitors. Viruses 2:1347-1366.
25. Michel, F., et al. 2009. Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor. EMBO J. 28:980-991.
26. Mouscadet, J. F., O. Delelis, A. G. Marcelin, and L. Tchertanov. 2010. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist Updat. 13:139-150.
27. Nowotny, M. 2009. Retroviral integrase superfamily: the structural perspective. EMBO Rep. 10:144-151.
28. Pannecouque, C., et al. 2002. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr. Biol. 12:1169-1177.
29. Perryman, A. L., et al. 2010. A dynamic model of HIV integrase inhibition and drug resistance. J. Mol. Biol. 397:600-615.
30. Pommier, Y., A. A. Johnson, and C. Marchand. 2005. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4:236-248.
31. Reigadas, S., et al. 2010. The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to raltegravir and impact the enzyme functions. PLoS One 5:e10311.
32. Reigadas, S., et al. 2010. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naïve and -experienced patients with different HIV-1 subtypes, abstr. 32, p. 31-32. Eighth Eur. Drug Resist. Workshop, Sorrento, Italy, 17 to 19 March 2010.
33. Sali, A., and T. L. Blundell. 1993. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234:779-815.
34. Savarino, A. 2007. In-silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 4:21.
35. Semenova, E. A., C. Marchand, and Y. Pommier. 2008. HIV-1 integrase inhibitors: update and perspectives. Adv. Pharmacol. 56:199-228.
36. Serrao, E., S. Odde, K. Ramkumar, and N. Neamati. 2009. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 6:25.
37. Steigbigel, R. T., et al. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.
38. Valkov, E., et al. 2009. Functional and structural characterization of the integrase from the prototype foamy virus. Nucleic Acids Res. 37:243-255.
39. Yang, W., and T. A. Steitz. 1995. Recombining the structures of HIV integrase, RuvC and RNase H. Structure 3:131-134.